Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idebenone - Chiesi Farmaceutici/Santhera Pharmaceuticals

Next Previous
Drug Profile

Idebenone - Chiesi Farmaceutici/Santhera Pharmaceuticals

Alternative Names: Catena; CV-2619; Puldysa; Raxone; SNTMC17; Sovrima

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Columbia University; National Institute of Neurological Disorders and Stroke; Santhera Pharmaceuticals; Takeda
  • Class Benzoquinones; Coenzymes; Eye disorder therapies; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leber's hereditary optic atrophy; Friedreich's ataxia; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leber's hereditary optic atrophy
  • Phase II Multiple sclerosis
  • Suspended Friedreich's ataxia
  • No development reported MELAS syndrome
  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 31 Jul 2023 Chiesi Farmaceutici acquires idebenone from Santhera Pharmaceuticals
  • 29 Nov 2022 No development reported - Preregistration for Leber's hereditary optic atrophy in South Korea (PO)
  • 25 Oct 2021 Santhera completes a phase III IONIA-E trial in Friedreich's ataxia (In adolescents, In children) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top